Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHORT-FOX: Short-course radiation and FOLFOXIRI for rectal cancer organ preservation
NCT04380337Phase 2
Key facts
- Status
- Completed
- Start
- May 2020
- Primary completion
- Jan 2024
- Countries
- 1
- Sponsor
- Stanford University
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Drugs
- FOLFIRINOX
- Conditions
- rectal cancer
01
Overview
Phase 2, open-label trial of FOLFIRINOX in rectal cancer, sponsored by Stanford University. Primary endpoint: Clinical Complete Response at 9 months. Started May 2020; status: completed.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Who it enrols
Patients with stage >T2N0 or low T2N0 rectal adenocarcinoma requiring TME, ECOG 0-2, with adequate organ function and no prior pelvic RT/chemo.
04
Endpoints
Primary
Clinical Complete Response
Beyond the preview
Go deeper on NCT04380337.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04380337.